Journal of clinical psychopharmacology|2026|Guerdjikova A, Walter L, McElroy S
PMID: 41632102
A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
Tirzepatide has been approved for the management of obesity, obstructive sleep apnea, and type 2 diabetes mellitus; while gastrointestinal side effects are commonly seen, ischemic colitis has been only rarely described. We present the case of a 32-ye…
BACKGROUND: The increasing use of GLP-1 receptor agonists for weight loss and metabolic improvements has led to the recognition of various side effects. One potential, yet underexplored, adverse effect is hair loss. This study aims to investigate the…
Incretins have improved the management of obesity and its related complications, but maintaining these health benefits requires ongoing administration, which can be challenging. Orforglipron, a once-daily oral nonpeptide glucagon-like peptide-1 (GLP-…
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used for the management of diabetes and obesity. However, adverse effects beyond gastrointestinal symptoms remain incompletely characterized. CASE SUMMARY: A 73-year-old w…
A sensitive and rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1…
AIMS: To characterize switching among GLP-1 receptor agonists (GLP-1 RAs) in a large private-sector cohort in Poland and to quantify therapy- and patient-level associations with switching while accounting for switching opportunity and calendar-time d…
The year 2025 represented a turning point in metabolic research, marked by advances that combined unprecedented clinical efficacy with deep mechanistic insight. Landmark obesity trials redefined therapeutic expectations, with head-to-head and combina…
PURPOSE: To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2026 in the United States, with a focus on the nonfederal hospital and clinic sec…
PURPOSE: This study presents an updated health economic model for evaluating the long-term cost-effectiveness of interventions in overweight and obesity, integrating new clinical evidence from the SURMOUNT clinical trial programme and methodological…
AIMS: We evaluated the impact of tirzepatide on health-related quality of life (HR-QoL) in Japanese individuals with obesity disease from the phase 3 SURMOUNT-J trial. MATERIALS AND METHODS: Japanese adults with obesity disease without diabetes were…
BACKGROUND: Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has gained widespread use for the treatment of type 2 diabetes mellitus, obesity, and obstructive sleep apnea. Th…
OBJECTIVE: To compare 1-year changes in estimated 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk following metabolic and bariatric surgery (MBS) versus glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy among adults…
Obesity is a chronic disease with a variety of metabolic, mechanical and psychosocial complications, including a high risk of developing prediabetes and subsequently type 2 diabetes mellitus. The choice of antidiabetic treatment as well as concomitan…
BACKGROUND: Compounded versions of tirzepatide are widely available in the U.S. in the form of fixed‑dose combinations of tirzepatide and various analogs of vitamin B12. These combinations are mass marketed in the U.S. and other countries as comparab…
We report the case of a 53-year-old woman with type 2 diabetes and bulimia nervosa who developed prolonged paralytic ileus after self-injecting tirzepatide 7.5 mg, 10 mg, and 15 mg on three consecutive days. Tirzepatide had been prescribed for diabet…